Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. (Q47550260)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28968735%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

title

Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28968735%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

1 reference

Christopher T Ritchlin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28968735%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Iain B McInnes

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28968735%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Philip J Mease

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28968735%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Proton Rahman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28968735%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Alice B Gottlieb

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28968735%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Bruce Kirkham

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28968735%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Radhika Kajekar

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28968735%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Eumorphia-Maria Delicha

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28968735%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Luminita Pricop

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28968735%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Shephard Mpofu

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28968735%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

publication date

1 November 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28968735%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28968735%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28968735%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28968735%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

page(s)

1993-2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28968735%20AND%20SRC:MED&resulttype=core&format=json

Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study

31 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5850284

Are psoriasis and psoriatic arthritis the same disease? The IL-23/IL-17 axis data.

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5850284

Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5850284

Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1).

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5850284

Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5850284

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5850284

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5850284

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5850284

World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5850284

Burden of disease: psoriasis and psoriatic arthritis

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5850284

Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5850284

A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5850284

Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials.

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5850284

Psoriatic arthritis: epidemiology, clinical features, course, and outcome

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5850284

Prevalence of joint disease in patients with psoriasis: implications for therapy

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5850284

Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5850284

Secukinumab in plaque psoriasis--results of two phase 3 trials

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5850284

Patient-reported Health-related Quality of Life with apremilast for psoriatic arthritis: a phase II, randomized, controlled study

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5850284

Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5850284

Work disability and health-related quality of life in males and females with psoriatic arthritis.

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5850284

When anti-TNF fails, anti-IL12-23 is an alternate option in psoriasis and psoriatic arthritis

14 August 2018

1 reference

12 December 2020

Recommendations for the management and treatment of psoriatic arthritis

1 reference

12 December 2020

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial

1 reference

12 December 2020

Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials

1 reference

12 December 2020

10.1093/RHEUMATOLOGY/KEX301

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28968735%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28968735%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

PubMed publication ID

28968735

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28968735%20AND%20SRC:MED&resulttype=core&format=json